References
- Chard DT, Dalton CM, Swanton J, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psych 2001;82:176-9
- Langer-Gould A, Brara S, Beaber B, et al. (2012). the incidence of clinically isolated syndrome is higher in African Americans and whites compared with Hispanics and Asians. Neurology 2012;78:Meeting Abstracts 1
- Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011;17:901-8
- Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-S85
- Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:1, 33-41.
- Dental and Pharmaceutical Benefits Agency. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm, Sweden: Dental and Pharmaceutical Benefits Agency. 2003. Available at: http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf. Accessed 14 March 2013
- Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford, England: Oxford University Press, 2006
- Tappenden P, Chilcott J, O’Hagan T, et al. (2001). Cost-effectiveness of beta-interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence. Sheffield, UK: School of Health and Related Research (ScHARR), 2001.
- World Health Organization/Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World. Switzerland, Geneva: World Health Organization. 2008
- Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:3-17
- Comi G, Freedman MS, De Stefano N, et al. Effect of two dosing frequencies of subcutaneous interferon beta-1a on conversion to MS and MRI measures of disease in patients with a first clinical demyelinating event: 3-year results of Phase III, double-blind, multicentre trials (REFLEX/REFLEXION). Lyon, France: ECTRIMS, 2012.
- Brex PA, Miszkiel KA, O'Riordan JI, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2001;70:390-3
- Kappos, L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
- GetData Graph Digitizer v2.24. 2012. http://getdata-graph-digitizer.com/. Accessed December 19, 2012.
- Oanda. New York, United States: OANDA Corporation. 2012. http://www.oanda.com/currency/historical-rates/. Accessed December 19, 2012.
- Statistics Sweden. Consumer Price Index. Stockholm, Sweden: Statistics Sweden. 2012. http://www.scb.se/Pages/TableAndChart____272152.aspx. Accessed February 28, 2013.
- Dental and Pharmaceutical Benefits Agency. Drug Price Database. Stockholm, Sweden: Dental and Pharmaceutical Benefits Agency. 2012. http://www.tlv.se/beslut/sok/lakemedel/. Accessed December 19, 2012.
- Statistics Sweden. Life tables 2006--2010. Stockholm, Sweden: Statistics Sweden. 2012. http://www.scb.se/Statistik/BE/BE0701/2001I10/Figur_3.xls. Accessed December 19, 2012.
- Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4
- Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(Suppl):S68-80
- Schwander B, Gradl B, Zöllner Y, et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe – The HEALTH Model. Value Health 2009;12:857-71
- Sorenson C. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison. Commonwealth Fund Pub 2010;91:1-13
- Polman CH, Reingold C, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
- Iskedjian M, Walker JH, Gray T, et al. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005;11:542-51
- Lazzaro C, Bianchi C, Peracino L, et al. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci 2009;3:21-31
- Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60